Phase 2 Readout~quarter
Phase 2 Readout: envudeucitinib
- Company
- ALUMIS INC. (ALMS)
- Drug
- envudeucitinib
Other upcoming events for ALMS
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.
Get real-time alerts, AI-powered analysis, and full catalyst coverage.